Marc Thill - Concepedia

Author

Marc Thill

Agaplesion Markus Hospital ORCID

Also Known As

Joachim Rom, M Thill, M. S. Thill, M. Thill, M., Thill, MARC THILL, Marc Thill, Martine Thill, Thill M, Thill, M.

520

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Agaplesion Markus Hospital University of Lübeck University Hospital Schleswig-Holstein Charité - Universitätsmedizin Berlin Heidelberg University

About

Marc Thill is an author at Agaplesion Markus Hospital specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	39	1.5K
2	Health Sciences	10	10	226
3	Nursing	5	5	263
4	Natural Sciences	1	1	10
5	Public Health	1	1	12

Marc Thill

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Annals of Oncology Advanced Breast CancerBreast OncologyOncologyPathologic Complete ResponsePathology	2022	365
Spatial predictors of immunotherapy response in triple-negative breast cancer Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, Nature	2023	278
The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope Marc Thill, Andrzej Kurylcio, Rebekka Welter, The Breast	2014	192
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016 Cornelia Liedtke, Marc Thill Breast Care Surgical OncologyBreast OncologyCancer ManagementAdjuvant ChemotherapyPathology	2016	188
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial Toralf Reimer, Angrit Stachs, Kristina Veselinovic, New England Journal of Medicine	2024	168
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial Luca Gianni, Mauro Mansutti, Antonio Antón, JAMA Oncology	2018	153
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Cancer Research Breast OncologyPathologic Complete ResponseHigh ProliferationImmunologyImmunoediting	2020	134
Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer Toralf Reimer, Angrit Stachs, Kristina Veselinovic, EClinicalMedicine	2022	88
Impact of cyclooxygenase-2 in breast cancer. Friederike Hoellen, Katharina Kelling, C. Dittmer, PubMed Tumor BiologyBreast OncologyProstaglandin SynthesisChemoprevention StrategyProstaglandin Metabolism	2011	61
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy Joerg Heil, André Pfob, Hans‐Peter Sinn, Annals of Surgery Surgical OncologyBreast OncologyPathologic Complete ResponsePathologySurgery	2020	60

Page 1